Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Gene Results

Back to Gene TablePrint


PALB2 gene

Associated Syndrome Name: PALB2-associated Cancer Risk

PALB2 Summary Cancer Risk Table

Cancer Genetic Cancer Risk
Female BreastHigh Risk
Male BreastElevated Risk
OvarianElevated Risk
PancreaticElevated Risk

PALB2 gene Overview

PALB2-associated Cancer Risk 1, 2, 3
  • Women with PALB2 mutations have a risk for breast cancer that is significantly increased over the 12.5% lifetime risk for women in the general population of the United States. Estimates of this risk vary and may be strongly influenced by other factors such as family history and when she was born. The highest risks for breast cancer seem to be in women with a family history of breast cancer and those where who were born more recently.
  • Women with PALB2 mutations have an increased risk for ovarian cancer. The 5% estimate in the Cancer Risk Table below is for women in the United Kingdom, where ovarian cancer is almost twice as common as in the United States. Therefore, risk may be lower for women in the United States. There is also evidence that the risk may be higher in women with a family history of ovarian cancer. At this time, there are no changes in medical management recommended for ovarian cancer risk due to a PALB2 mutation.
  • Men and women with PALB2 mutations have a small increased risk for pancreatic cancer. Pancreatic cancer screening is only recommended for individuals with a PALB2 mutation if there have been past diagnoses of pancreatic cancer in the family.
  • Men with PALB2 mutations have an increased risk for male breast cancer. Although the breast cancer risk is significantly increased over that for men without PALB2 mutations, the absolute risk of male breast cancer remains small.
  • There is some evidence that men and women with mutations in PALB2 have an increased risk for gastric cancer. However, at this time, the evidence is not conclusive and there are no management recommendations for gastric cancer risk.
  • Although there are increased risks for cancer in men and women with mutations in PALB2, there are interventions that may reduce these risks. Guidelines from the National Comprehensive Cancer Network (NCCN) that may apply are listed below. Since information about the cancer risks associated with PALB2 mutations is relatively new, and there is still some uncertainty about the best ways to reduce these risks, it may be appropriate to interpret these results in consultation with cancer genetics experts in this emerging area of knowledge.

PALB2 gene Cancer Risk Table

Cancer Type Age Range Cancer Risk Risk for General Population
Female BreastTo age 503, 417%1.9%
To age 803, 453%10.2%
PancreaticTo age 803, 42%-3%1%
OvarianTo age 803, 45%1.0%
Male BreastTo age 803, 41%0.1%

PALB2 Cancer Risk Management Table

The overview of medical management options provided is a summary of professional society guidelines. The most recent version of each guideline should be consulted for more detailed and up-to-date information before developing a treatment plan for a particular patient.

This overview is provided for informational purposes only and does not constitute a recommendation. While the medical society guidelines summarized herein provide important and useful information, medical management decisions for any particular patient should be made in consultation between that patient and his or her healthcare provider and may differ from society guidelines based on a complete understanding of the patient’s personal medical history, surgeries and other treatments.

Cancer Type Procedure Age to Begin Frequency
(Unless otherwise indicated by findings)
Female BreastBreast awareness - Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast self-examination (BSE) may facilitate breast awareness.5IndividualizedNA
Clinical encounter, including clinical breast exam, ongoing risk assessment and risk-reduction counseling5When genetic risk is identifiedEvery 6 to 12 months
Mammography with consideration of tomosynthesis and breast MRI with contrast6Age 30, or modified to a younger age based on family historyAnnually
Consider risk-reducing mastectomy.6IndividualizedNA
Consider additional risk-reduction strategies.5, 6IndividualizedNA
PancreaticFor patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in screening for pancreatic cancer, preferably within research protocols.7, 8Age 50, or 10 years younger than the earliest age of pancreatic cancer diagnosis in the familyAnnually
Provide education about ways to reduce pancreatic cancer risk, such as not smoking and losing weight.7, 9IndividualizedIndividualized
OvarianCurrently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers.NANA
Male BreastCurrently there are no specific medical management guidelines for breast cancer risk in mutation carriers. However, the increase in risk warrants consideration of options for male breast cancer screening, such as patient breast awareness education and clinical breast examinations.5, 6IndividualizedNA
For Patients With A Cancer DiagnosisFor patients with a gene mutation and a diagnosis of cancer, targeted therapies may be available as a treatment option for certain tumor types (e.g., platinum chemotherapy, PARP-inhibitors)9NANA

Information for Family Members

The following information for Family Members will appear as part of the MMT for a patient found to have a mutation in the PALB2 gene.

A major potential benefit of myRisk genetic testing for hereditary cancer risk is the opportunity to prevent cancer in relatives of patients in whom clinically significant mutations are identified. Healthcare providers have an important role in making sure that patients with clinically significant mutations are informed about the risks to relatives, and ways in which genetic testing can guide lifesaving interventions.

In rare instances, an individual may inherit mutations in both copies of the PALB2 gene, leading to the condition Fanconi Anemia, Complementation Group N (FANCN). This condition is extremely rare, but is thought to include physical abnormalities, growth retardation, progressive bone marrow failure and a high risk for cancer. The children of this patient are at risk of inheriting FANCN only if the other parent is also a carrier of a PALB2 mutation. Screening the other biological parent of any children for PALB2 mutations may be appropriate.10

References

  1. Ajani JA, et al. NCCN Clinical Practice Guidelines in Oncology®: Gastric Cancer. V 4.2019. Dec 20. Available at http://www.nccn.org.
  2. Lott PC, et al. Resolving gastric cancer aetiology: an update in genetic predisposition. Lancet Gastroenterol Hepatol. 2018 3:874-883. PMID: 30507471.
  3. Yang X, et al. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2019 Dec 16 [Epub ahead of print] PMID: 31841383.
  4. Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/faststats. (Accessed on 1-2-2017)
  5. Bevers TB, et al. NCCN Clinical Practice Guidelines in Oncology®: Breast Cancer Screening and Diagnosis. V 1.2019. May 17. Available at http://www.nccn.org.
  6. Daly M et al. NCCN Clinical Practice Guidelines in Oncology®: Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic. V 1.2020. Dec 4. Available at http://www.nccn.org.
  7. Syngal S, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015 110:223-62. PMID: 25645574.
  8. Goggins M, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020 69:7-17. PMID: 31672839.
  9. Tempero MA, et al. NCCN Clinical Practice Guidelines in Oncology®: Pancreatic Adenocarcinoma. V 1.2020. Nov 26. Available at http://www.nccn.org.
  10. Reid S, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007 39:162-4. PMID: 17200671.
Last Updated on 10-Sep-2020